avacincaptad pegol
Generic: ACP·Brand: IZERVAY·Code: OPH2003, ISEE2008
avacincaptad pegol: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| IVERIC bio, Inc. (ISEE) | Phase 2/Phase 3 |
Clinical Trials (1)
A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Frequently asked questions
Who is developing avacincaptad pegol?
avacincaptad pegol is being developed by IVERIC bio, Inc..
How many clinical trials involve avacincaptad pegol?
BioSniper tracks 1 clinical trial involving avacincaptad pegol.
Get deeper analysis on avacincaptad pegol
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis